We speculate that exploring the clinical feasibility of PPARβ/δ antagonists in cancer treatment may result in fruitful outcomes considering the involvement of PPARβ/δ in tumorigenesis processes like oxidative stress homeostasis, differentiation of tumor-associated macrophages, angiogenesis, and epithelial-mesenchymal transition [329,330,331]. Here, PPARD is linked to cancer.